Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to Alleviate Atherosclerosis

Overview

Journal Diseases

Date 2018 Sep 20

PMID 30227643

Citations 3

Authors

Zainab Jahangir

Ahmed Bakillah

Jahangir Iqbal

Affiliations

Soon will be listed here.

Abstract

The rapidly expanding field of bioactive lipids is exemplified by the many sphingolipids, which are structurally and functionally diverse molecules with significant physiologic functions. These sphingolipids are main constituents of cellular membranes and have been found associated with plasma lipoproteins, and their concentrations are altered in several metabolic disorders such as atherosclerosis, obesity, and diabetes. Understanding the mechanisms that regulate their biosynthesis and secretion may provide novel information that might be amenable to therapeutic targeting in the treatment of these diseases. Several sphingolipid synthesis genes have been targeted as potential therapeutics for atherosclerosis. In recent years, significant progress has been made in studying the role of microRNAs (miRNAs) in lipid metabolism. However, little effort has been made to investigate their role in sphingolipid metabolism. Sphingolipid biosynthetic pathways involve various enzymes that lead to the formation of several key molecules implicated in atherosclerosis, and the identification of miRNAs that regulate these enzymes could help us to understand these complex pathways better and may prove beneficial in alleviating atherosclerosis.

Citing Articles

The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction.

Ji Y, Chen J, Pang L, Chen C, Ye J, Liu H Cardiovasc Drugs Ther. 2022; 38(1):43-56.

PMID: 36103099 PMC: 10876840. DOI: 10.1007/s10557-022-07378-0.

LncRNA MALAT1 Suppression Protects Endothelium against oxLDL-Induced Inflammation via Inhibiting Expression of MiR-181b Target Gene TOX.

Wang L, Qi Y, Wang Y, Tang H, Li Z, Wang Y Oxid Med Cell Longev. 2020; 2019:8245810.

PMID: 31949884 PMC: 6942911. DOI: 10.1155/2019/8245810.

Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.

Dasgupta S, Ray S Int J Mol Sci. 2019; 20(20).

PMID: 31614447 PMC: 6834223. DOI: 10.3390/ijms20205031.

References

Park T, Panek R, Mueller S, Hanselman J, Rosebury W, Robertson A . Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2004; 110(22):3465-71. DOI: 10.1161/01.CIR.0000148370.60535.22. View

Li Z, Fan Y, Liu J, Li Y, Huan C, Bui H . Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012; 32(7):1577-84. PMC: 3444302. DOI: 10.1161/ATVBAHA.112.251538. View

Rayner K, Suarez Y, Davalos A, Parathath S, Fitzgerald M, Tamehiro N . MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010; 328(5985):1570-3. PMC: 3114628. DOI: 10.1126/science.1189862. View

Scholer N, Langer C, Dohner H, Buske C, Kuchenbauer F . Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol. 2010; 38(12):1126-30. DOI: 10.1016/j.exphem.2010.10.004. View

Lallemand T, Rouahi M, Swiader A, Grazide M, Geoffre N, Alayrac P . nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe Mice. Arterioscler Thromb Vasc Biol. 2018; 38(7):1479-1492. PMC: 6039418. DOI: 10.1161/ATVBAHA.118.311208. View

Glaros E, Kim W, Wu B, Suarna C, Quinn C, Rye K . Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol. 2007; 73(9):1340-6. DOI: 10.1016/j.bcp.2006.12.023. View

Pewzner-Jung Y, Ben-Dor S, Futerman A . When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem. 2006; 281(35):25001-5. DOI: 10.1074/jbc.R600010200. View

Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo M . Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res. 2009; 105(3):295-303. PMC: 2746935. DOI: 10.1161/CIRCRESAHA.109.194613. View

Christian P, Su Q . MicroRNA regulation of mitochondrial and ER stress signaling pathways: implications for lipoprotein metabolism in metabolic syndrome. Am J Physiol Endocrinol Metab. 2014; 307(9):E729-37. DOI: 10.1152/ajpendo.00194.2014. View

10.

Chen M, Yang L, Lu P, Fu X, Zhang Y, Zhu Y . MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells. Biochem Biophys Res Commun. 2015; 463(4):954-60. DOI: 10.1016/j.bbrc.2015.06.041. View

11.

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

12.

Filipowicz W, Bhattacharyya S, Sonenberg N . Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008; 9(2):102-14. DOI: 10.1038/nrg2290. View

13.

Kurano M, Yatomi Y . Sphingosine 1-Phosphate and Atherosclerosis. J Atheroscler Thromb. 2017; 25(1):16-26. PMC: 5770220. DOI: 10.5551/jat.RV17010. View

14.

Lusis A . Atherosclerosis. Nature. 2000; 407(6801):233-41. PMC: 2826222. DOI: 10.1038/35025203. View

15.

Aryal B, Singh A, Rotllan N, Price N, Fernandez-Hernando C . MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017; 28(3):273-280. PMC: 5667558. DOI: 10.1097/MOL.0000000000000420. View

16.

Ogretmen B, Hannun Y . Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004; 4(8):604-16. DOI: 10.1038/nrc1411. View

17.

Glass C, Witztum J . Atherosclerosis. the road ahead. Cell. 2001; 104(4):503-16. DOI: 10.1016/s0092-8674(01)00238-0. View

18.

Kasumov T, Li L, Li M, Gulshan K, Kirwan J, Liu X . Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One. 2015; 10(5):e0126910. PMC: 4439060. DOI: 10.1371/journal.pone.0126910. View

19.

Glaros E, Kim W, Quinn C, Jessup W, Rye K, Garner B . Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J Lipid Res. 2007; 49(2):324-31. DOI: 10.1194/jlr.M700261-JLR200. View

20.

Iqbal J, Walsh M, Hammad S, Hussain M . Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends Endocrinol Metab. 2017; 28(7):506-518. PMC: 5474131. DOI: 10.1016/j.tem.2017.03.005. View